Market Overview

Endo Health Solutions to Buy Boca Pharmacal for $225M

Related ENDP
Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
US Stock Futures Up Ahead Of Economic Data

Endo Health Solutions (NASDAQ: ENDP) today announced that its Qualitest subsidiary has reached a definitive agreement to acquire privately held Boca Pharmacal, a specialty generics company, for $225 million in cash.  The transaction is expected to enhance the growth platform and pipeline for Endo's Qualitest business and is consistent with Endo's strategic transformation into a leading specialty healthcare company.

Posted-In: News M&A

 

Related Articles (ENDP)

Around the Web, We're Loving...

Get Benzinga's Newsletters